A Safety and Efficacy Study to Evaluate Rosacea
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cosmetic |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 3/27/2019 |
| Start Date: | August 2019 |
| End Date: | September 2020 |
| Contact: | Catawba Research |
| Email: | Caryn@CatawbaResearch.com |
| Phone: | 1-980-242-3980 |
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Intradermally Administered AIV001 in Subjects With Papulopustular Rosacea
To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of
the study medication compared with vehicle in subjects with rosacea.
the study medication compared with vehicle in subjects with rosacea.
This is primarily a safety study to evaluate the safety of AIV001 when administered to
subjects with rosacea. Exploratory efficacy measures will also be collected as well as
pharmacokinetic profiles.
subjects with rosacea. Exploratory efficacy measures will also be collected as well as
pharmacokinetic profiles.
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 18 and 65 year with rosacea,
10 to 30 papules and pustules (at least 5 lesions within the treatment area on each
facial side), and < 2 nodules
- Presence of moderate to severe persistent erythema
- Total body weight >45 kg
Exclusion Criteria:
- Presence of any skin condition on the face that would interfere with the diagnosis or
assessment of rosacea
- Extremely dark skin type that would confound the digital analysis of erythema (eg,
Fitzpatrick Skin Type 5 or 6)
- Excessive facial hair (eg, beards, sideburns, moustaches, etc.), birthmarks, or
tattoos that would interfere with diagnosis or assessment of rosacea
- Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
cigarettes per day.
- Pregnant or nursing females; females of childbearing potential who are unwilling or
unable to use an acceptable method of non-hormonal contraception as outlined in this
protocol from at least 14 days prior to start of treatment.
- Hypersensitivity or allergy to axitinib or any other component of the study treatment
- Use within 6 months prior to baseline and during the study of oral retinoids (eg,
Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day
(multivitamins are allowed).
- Use within 6 weeks prior to baseline and during the study of vasodilators or
α-adrenergic receptor-blocking agents.
- Use within 1 month prior to baseline and during the study of 1) topical retinoids to
the face, 2) systemic antibiotics know to have an impact on the severity of facial
rosacea (eg, containing tetracycline and its derivatives, erythromycin and its
derivatives, sulfamethoxazole, or trimethoprim), 3) systemic corticosteroids, or 4)
facial light-based therapies
We found this trial at
1
site
Click here to add this to my saved trials
